BioSpace News Archive

Digital Health Impact – Aimed at offering more effective drugs at a lower cost to cancer patients turning to photomedicine as an alternative to chemotherapy, a grant from the Massachusetts Life Sciences Center (MLSC) will have chemical and data scientists working side by side at the Lopez Lab of Boston’s Northeastern University and the Cambridge facilities of Kebotix, an artificial intelligence technology company for new chemicals and materials.

NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, today announced that it has completed construction on its new 25,000 square foot, state-of-the-art cell therapy manufacturing facility.

The September 10 hearing on the Temporary Restraining Order (TRO) issued against Blue Cross Blue Shield of Texas (BCBS) by the 50th District Court of Texas has been postponed pending the BCBS effort to have the case moved to federal court.

Compounded drugs can serve an important medical need for certain patients, however, they also present risks to patients since they are not evaluated by the FDA for safety, effectiveness and quality.

Welltower Inc. (NYSE: WELL) today announced that it was recently included as a featured company on Morgan Stanley’s ’30 for 2021: Quality Stocks for a Long-Term Holding Period’ list. On Friday, September 6th, Welltower Chairman and CEO Thomas J. DeRosa represented the Company in a panel discussion at the Morgan Stanley Quality Stock Summit.

Global clinical program is the first to study this severely ill patient population, who are typically excluded from antidepressant treatment studies

The Company has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,478,873 common shares from the Company on the same terms and conditions.

Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that the Company will present at the upcoming Annual CAR-TCR Summit in Boston, MA September 10-13, 2019.

Gene therapy product WP-REP1 comprised of DNA nanoparticles to treat the Inherited Retinal Disease Choroideremia

Ready-to-use kit enables lentivirus titer determinations during the manufacture of lentivirus vectors